Abstract
When a 50-year drought without a single new tuberculosis drug ended in 2012 with the approval of two new medicines, delamanid and bedaquiline, the tuberculosis community was poised for fast improvements to multidrug resistant (MDR) tuberculosis care and cure rates. Yet, 5 years later, the new medications are still not used widely enough in the areas most affected by MDR tuberculosis. Will recent evidence of their safety and effectiveness finally tip the scale and substantially improve MDR tuberculosis care?
